Cambridge Healthtech Institute’s 2nd Annual

Cancer Biotherapeutics
6-7 November 2014


Research in 2014 for this event reveals a huge increase in the interest in immunotherapy and continued interest in bi-and multi-specific products, combination approaches, and antibody drug conjugates. This conference track will present advances in all of these areas from discovery to development, and provide details on innovative modes of action, and on application and efficacy.  Safety considerations for these new approaches will also be covered.


Topics will include, but are not limited to, the following: 


1. Immunotherapy. For example: The very hot topics of CTLA4, PD1, and PDL1; targeting CD3 and/or the T cell MHC complex in combination with cancer targets; bi-specifics that engage T cells; safety challenges of immune system activating cells.

2. Novel engineering approaches, especially for bi- and multi-specific antibodies for cancer 

3. Developments with ADCs.  For example: Demonstration of efficacy and biodistribution; how and where to use site-specific conjugation; linker technologies; bi-specific ADCs; critical issues for taking ADCs into the clinic and building an IND.

4. Unusual combination therapies of drugs acting in synergy 

5. Focus on novel or unusual targets such as ones for cell proliferation, angiogenesis and metastasis and on accessing difficult targets 

6. Preclinical, translational and clinical studies.  For example: Strategies for entering the clinic; proof of concept studies; dose and efficacy data; how pre-clinical findings translate into the clinic

7. Optimization of cancer biotherapeutics. For example: Platform development; development of manufacture; enhanced efficacy 


If you would like to submit a proposal to give a presentation at this meeting, please click here.


Deadline for submission is 21 March 2014 


All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact: 

Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
Tel: +44 7791 866489


For exhibit & sponsorship opportunities, please contact: 

Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471